Brad S. Kahl

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text

Medicine, Hematology, Pharmacology +17

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elı́as Campo, Elaine S. Jaffe, James R. Cook et al. · Blood · 2022 · 1.5K citations · Full text

Veterinary Medicine, Hematology, Oncology +17

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 751 citations

Medicine, Hematology, Pharmacokinetics +15